P300 component of event-related potentials in methamphetamine psychosis and schizophrenia

Iwanami, Akira; Suga, Ichiro; Kaneko, Tsuguo; Sugiyama, Azusa; Nakatani, Yoji

doi:10.1016/0278-5846(94)90004-3

Cited by 20 publications

(4 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However their study, unlike ours, did not find significant differences in P300 amplitudes between drug users and controls. A follow up study by the same group ( Iwanami et al, 1994 ) found significant differences in P300 amplitudes between methamphetamine psychotics and controls in the Fz and Cz electrodes, similar to our results where we found maximum P300 amplitude differences in FPz electrode. In addition, brain imaging studies of methamphetamine abusers have found decreased cerebral blood flow in putamen cortices and right lateral parietal cortex, but increased blood flow in the left temporo-parietal white matter, left occipital regions, and right posterior parietal regions ( Chang et al, 2002 ).…”

Section: Discussionsupporting

confidence: 91%

“…Two well-known studies based on auditory stimuli ( Iwanami, Suga, Kato, Nakatani, & Kaneko, 1993 ; Iwanami, Suga, Kaneko, Sugiyama, & Nakatani, 1994 ) investigated the ERP changes among methamphetamine drug abusers and will be discussed in detail in section 4.1. In addition, few EEG-based studies have shown different quantitative EEG (QEEG) responses between methamphetamine-dependent subjects and controls ( Newton et al, 2003 ; Newton et al, 2004 ) and between ecstasy-dependent subjects and controls ( Dafters, Duffy, O’Donnell, & Bouquet, 1999 ).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Neural Correlates of Craving in Methamphetamine Abuse

Shahmohammadi¹,

Golesorkhi²,

Kashani³

et al. 2016

BCN

View full text Add to dashboard Cite

Introduction:Methamphetamine is a powerful psychostimulant that causes significant neurological impairments with long-lasting effects and has provoked serious international concerns about public health. Denial of drug abuse and drug craving are two important factors that make the diagnosis and treatment extremely challenging. Here, we present a novel and rapid noninvasive method with potential application for differentiation and monitoring methamphetamine abuse.Methods:Visual stimuli comprised a series of images with neutral and methamphetamine-related content. A total of 10 methamphetamine abusers and 10 age-gender matched controls participated in the experiments. Event-related potentials (ERPs) were recorded and compared using a time window analysis method. The ERPs were divided into 19 time windows of 100 ms with 50 ms overlaps. The area of positive sections below each window was calculated to measure the differences between the two groups.Results:Significant differences between two groups were observed from 250 to 500 ms (P300) in response to methamphetamine-related visual stimuli and 600 to 800 ms in response to neutral stimuli.Conclusion:This study presented a novel and noninvasive method based on neural correlates to discriminate healthy individuals from methamphetamine drug abusers. This method can be employed in treatment and monitoring of the methamphetamine abuse.

show abstract

Section: Discussionsupporting

confidence: 91%

Section: Introductionmentioning

confidence: 99%

Neural Correlates of Craving in Methamphetamine Abuse

Shahmohammadi¹,

Golesorkhi²,

Kashani³

et al. 2016

BCN

View full text Add to dashboard Cite

show abstract

“…The few studies that compared schizophrenia with other psychotic disorders on auditory target P300 amplitude have yielded mixed results (Iwanami et al, 1994; Hermens et al, 2010; Kaur et al, 2012; Kaur et al, 2011; Salisbury et al, 1998; Salisbury et al, 1999; Ethridge et al, 2012; Mathalon et al, 2010). Consequently, it is unclear whether P300 amplitude reduction is best conceptualized as a unique characteristic of schizophrenia or a transdiagnostic indicator of psychosis.…”

Section: Introductionmentioning

confidence: 99%

“…In particular, many patients diagnosed initially with other psychoses were reclassified with schizophrenia at follow-up. Prior studies comparing P300 amplitude between schizophrenia and other psychotic disorders may have been subject to misclassification confounds due to a focus on recent-onset psychosis and/or lack of longer-term follow-up (Iwanami et al, 1994; Hermens et al, 2010; Kaur et al, 2012; Kaur et al, 2011; Salisbury et al, 1998; Salisbury et al, 1999; Ethridge et al, 2012; Mathalon et al, 2010). Thus, very little is known about auditory target P300 in psychotic disorders with diagnoses ascertained longitudinally to minimize misclassification.…”

Section: Introductionmentioning

confidence: 99%

Clinical significance of auditory target P300 subcomponents in psychosis: Differential diagnosis, symptom profiles, and course

Foti¹,

Jackson²,

Kotov³

et al. 2015

Schizophrenia Research

View full text Add to dashboard Cite

Background Reduced auditory target P300 amplitude is a leading biomarker for psychotic disorders, although its relevance for differential diagnosis and link to specific clinical features (symptom profiles, functional impairment, and course) is unclear. This study aims to clarify the clinical significance of auditory target P300 using concurrent and retrospective clinical data from a longitudinal cohort with psychosis. Methods 92 cases from an epidemiological study of first-admission psychosis were assessed using an auditory oddball paradigm at 15-year follow-up along with 44 never-psychotic adults. Subcomponents of auditory target P300 amplitude (i.e., a central positive P3a, a parietal positive P3b, and a frontal negative slow wave) were isolated using temporal-spatial principal components analysis. Results P3a amplitude was blunted across psychotic disorders relative to non-psychotic adults. P3b amplitude was reduced in schizophrenia specifically, including cases initially misclassified at baseline. The frontal negative slow wave did not distinguish among groups. P3b amplitude reduction was associated with several clinical features at the concurrent assessment, as well as previous time points, including recovery from psychosis even 5 years earlier and functioning even 15 years earlier. Conclusions Auditory target P300 amplitude yields both a schizophrenia-specific component (i.e., P3b) and a transdiagnostic psychosis component (i.e., P3a). The P3b component may also shed light on prognosis, real-world functioning, and course, as well as help to reduce misdiagnosis of psychotic disorders. Prospective studies are needed to test whether P3b tracks or predicts clinical status.

show abstract

EEG Biofeedback as a Treatment for Substance Use Disorders: Review, Rating of Efficacy, and Recommendations for Further Research

Sokhadze

Cannon

Trudeau

2008

Appl Psychophysiol Biofeedback

167

View full text Add to dashboard Cite

Electroencephalographic (EEG) biofeedback has been employed in substance use disorder (SUD) over the last three decades. The SUD is a complex series of disorders with frequent comorbidities and EEG abnormalities of several types. EEG biofeedback has been employed in conjunction with other therapies and may be useful in enhancing certain outcomes of therapy. Based on published clinical studies and employing efficacy criteria adapted by the Association for Applied Psychophysiology and Biofeedback and the International Society for Neurofeedback and Research, alpha theta training-either alone for alcoholism or in combination with beta training for stimulant and mixed substance abuse and combined with residential treatment programs, is probably efficacious. Considerations of further research design taking these factors into account are discussed and descriptions of contemporary research are given.

show abstract

P300 component of event-related potentials in methamphetamine psychosis and schizophrenia

Cited by 20 publications

References 14 publications

Neural Correlates of Craving in Methamphetamine Abuse

Neural Correlates of Craving in Methamphetamine Abuse

Clinical significance of auditory target P300 subcomponents in psychosis: Differential diagnosis, symptom profiles, and course

EEG Biofeedback as a Treatment for Substance Use Disorders: Review, Rating of Efficacy, and Recommendations for Further Research

Contact Info

Product

Resources

About